Nohria Ambika, Kaslow Sarah R, Hani Leena, He Yanjie, Sacks Greg D, Berman Russell S, Lee Ann Y, Correa-Gallego Camilo
Department of Surgery, New York University Grossman School of Medicine, New York, New York.
Department of Surgery, New York University Grossman School of Medicine, New York, New York.
J Surg Res. 2022 Nov;279:304-311. doi: 10.1016/j.jss.2022.06.018. Epub 2022 Jul 6.
Surgery is an option for symptom palliation in patients with metastatic gastric cancer. Operative outcomes after palliative interventions are largely unknown. Herein, we assess the trends of surgical palliation use for patients with gastric cancer and describe outcomes of patients undergoing surgical palliation compared to nonsurgical palliation.
Patients with clinical Stage IV gastric cancer in the National Cancer Database (2004-2015) who received surgical or nonsurgical palliation were selected. We identified factors associated with palliative surgery. Survival differences were assessed by Kaplan-Meier estimate, Cox proportional hazard regression, and log rank test.
Six thousand eight hundred twenty nine patients received palliative care for gastric cancer. Most patients (87%, n = 5944) received nonsurgical palliation: 29% radiation therapy, 57% systemic treatment, and 14% pain management. The number of patients receiving palliative care increased between 2004 and 2015; however, use of surgical palliation declined significantly (22% in 2004, 8% in 2015; P < 0.001). Median overall survival (OS) for the cohort was 5.65 mo (95% confidence interval 5.45-5.85); 1-year and 2-year OS were 24% and 9%, respectively. Older age at diagnosis and diagnosis between 2004 and 2006 were significantly associated with undergoing surgical palliation. Patients who underwent surgical palliation had significantly shorter median OS and a 20% higher hazard of mortality than those who received nonsurgical palliation.
Patients with metastatic gastric cancer experience very short survival. While palliative surgery is used infrequently, the observed association with shorter median OS underscores the importance of careful patient selection. Palliative surgery should be offered judiciously and expectations about outcomes clearly established.
手术是转移性胃癌患者症状缓解的一种选择。姑息性干预后的手术结果在很大程度上尚不清楚。在此,我们评估了胃癌患者手术姑息治疗的使用趋势,并描述了接受手术姑息治疗与非手术姑息治疗患者的结局。
选择国家癌症数据库(2004 - 2015年)中接受手术或非手术姑息治疗的临床IV期胃癌患者。我们确定了与姑息性手术相关的因素。通过Kaplan - Meier估计、Cox比例风险回归和对数秩检验评估生存差异。
6829例患者接受了胃癌姑息治疗。大多数患者(87%,n = 5944)接受非手术姑息治疗:29%为放射治疗,57%为全身治疗,14%为疼痛管理。2004年至2015年期间接受姑息治疗的患者数量有所增加;然而,手术姑息治疗的使用显著下降(2004年为22%,2015年为8%;P < 0.001)。该队列的中位总生存期(OS)为5.65个月(95%置信区间5.45 - 5.85);1年和2年OS分别为24%和9%。诊断时年龄较大以及在2004年至2006年期间诊断与接受手术姑息治疗显著相关。接受手术姑息治疗的患者中位OS显著较短,死亡风险比接受非手术姑息治疗的患者高20%。
转移性胃癌患者生存期非常短。虽然手术姑息治疗使用较少,但观察到的与较短中位OS的关联强调了谨慎选择患者的重要性。应谨慎提供手术姑息治疗,并明确对结局的预期。